Drug Trial Radar · NCT04456816
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
23
Planned (sponsor's estimate)
Start
Aug 31, 2020
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.
Conditions
- Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Severe Proteinuria Due to Idiopathic Membranous Nephropathy
Interventions
100 mg AP1189Drug
100 mg AP1189 tablet
PlaceboDrug
Matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Week 12
- Serious Adverse EventsTime frame: Week 12
- ALAT change in plasma samplesTime frame: Week 12
- ASAT change in plasma samplesTime frame: Week 12
- Total bilirubin change in plasma samplesTime frame: Week 12
- Alkaline phosphatase change in plasma samplesTime frame: Week 12
- Protein change in 24 hours urinary protein excretionTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aarhus Universitetshospital
Aarhus, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.